Screening for prostate cancer using multivariate mixed-effects models

Journal of Applied Statistics

Volumn 39, Issue 6, 2012, Pages 1151-1175

  Morrell, Christopher H ^a,b   Brant, Larry J ^b   Sheng, Shan ^b   Metter, E Jeffrey ^b  

^a LOYOLA UNIVERSITY MARYLAND   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

classification; disease screening; longitudinal data; sensitivity; specificity

Indexed keywords

EID: 84859772296     PISSN: 02664763     EISSN: 13600532     Source Type: Journal    
DOI: 10.1080/02664763.2011.644523     Document Type: Article

References (44)

1. Brant, L. J., Sheng, S. L., Morrell, C. H., Verbeke, G. N., Lesaffre, E. and Carter, H. B. 2003. Screening for prostate cancer by using random-effects models. J. Roy. Stat. Soc.: Ser. A, 166: 51-62.
2. Cadeddu, J. A., Pearson, J. D., Partin, A. W., Epstein, J. I. and Carter, H. B. 1993. Relationship between changes in prostate-specific antigen and prognosis of prostate cancer. Urology, 42: 383-389.
3. Carter, H. B. and Coffey, D. S. 1990. The prostate: An increasing medical problem. Prostate, 16: 39-48.
4. Carter, H. B. and Pearson, J. D. 1994. Evaluation of changes in PSA in the management of men with prostate cancer. Semin. Oncol, 21(5): 554-559.
5. Carter, H. B., Pearson, J. D., Metter, E. J., Brant, L. J., Chan, D. W., Andres, R., Fozard, J. L. and Walsh, P. C. 1992. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. J. Am. Med. Assoc., 267: 2215-2220.
6. Catalona, W. J., Smith, D. S., Ratliff, T. L., Dodds, K. M., Coplen, D. E., Yuan, J. J., Petros, J. A. and Andriole, G. L. 1991. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. New England J. Med., 324: 1156-1161.
7. Chaganty, N. R. and Naik, D. N. 2002. Analysis of multivariate longitudinal data using quasi-least squares. J. Stat. Planning Inference, 103(1-2): 421-436.
8. Collin, S., Martin, R., Metcalfe, C., Gunnell, D., Albertsen, P., Neal, D., Hamdy, F., Stephens, P., Lane, J. and Moore, R. 2008. Prostate-cancer mortality in the USA and UK in 1975-2004: An ecological study. Lancet Oncol., 9(5): 445-452.
9. Cook, N. R. 2007. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation, 115: 928-935.
10. Cook, N. R. 2008. Statistical evaluation of prognostic versus diagnostic models: Beyond the ROC curve. Clin. Chem., 54(1): 17-23.
11. D'Amico, A. V., Whittington, R., Malkowicz, S. B., Weinstein, M., Tomaszewski, J. E., Schultz, D., Rhude, M., Rocha, S., Wein, A. and Richie, J. P. 2001. Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. J. Urol., 166: 2185-2188.
12. Diggle, P. J. 1990. Time Series: A Biostatistical Introduction, Oxford: Oxford Science Publications.
13. Fieuws, S. and Verbeke, G. 2006. Pairwise fitting of mixed models for the joint modelling of multivariate longitudinal profiles. Biometrics, 62(2): 424-431.
14. S. Fieuws, G. Verbeke, and L.J. Brant, Classification of longitudinal profiles using nonlinear mixed-effects models, Technical Report TR0356, Interuniversity Attraction Pole, IAP Statistics Network, 2003. Available at http://www.stat.ucl.ac.be/IAP/.
15. Fieuws, S., Verbeke, G., Maes, B. and Vanrenterghem, Y. 2008. Predicting renal graft failure using multivariate longitudinal profiles. Biostatistics, 9(3): 419-431.
16. Giovannucci, E., Rimm, E. B., Liu, Y., Leitzmann, M., Wu, K., Stampfer, M. J. and Willett, W. C. 2003. Body mass index and risk of prostate cancer in U.S. health professionals. J. National Cancer Inst., 95(16): 1240-1244.
17. Green, D. M. and Swets, J. A. 1988. Signal Detection Theory and Psychophysics, Los Altos, CA: Peninsula Publishing.
18. Inoue, L. Y.T., Etzioni, R., Morrell, C. H. and Muller, P. 2008. Modeling disease progression with longitudinal markers. J. Am. Stat. Assoc., 103: 259-270.
19. Kane, C. J., Bassett, W. W., Sadetsky, N., Silva, S., Wallace, K., Pasta, D. J., Cooperberg, M. R., Chan, J. M. and Carroll, P. R. 2005. Obesity and prostate cancer clinical risk factors at presentation: Data from CaPSURE. J. Urol., 173(3): 732-736.
20. Lin, H., McCulloch, C. E. and Mayne, S. T. 2002. Maximum likelihood estimation in the joint analysis of time-to-event and multiple longitudinal variables. Stat. Med., 21: 2369-2382.
21. Lin, H., Turnbull, B. W., McCulloch, C. E. and Slate, E. H. 2002. Latent class models for joint analysis of longitudinal biomarker and event process data: Application to longitudinal prostate-specific antigen readings and prostate cancer. J. Am. Stat. Assoc., 97: 53-65.
22. Liu, M., Taylor, J. M.G. and Belin, T. R. 2000. Multiple imputation and posterior simulation for multivariate missing data in longitudinal studies. Biometrics, 56: 1157-1163.
23. McIntosh, M. W. and Urban, N. 2003. A parametric empirical Bayes method for cancer screening using longitudinal observations of a biomarker. Biostatistics, 4: 27-40.
24. Morrell, C. H., Pearson, J. D. and Brant, L. J. 1997. Linear transformations of linear mixed-effects models. Am. Stat., 51: 338-343.
25. Morrell, C. H., Pearson, J. D., Carter, H. B. and Brant, L. J. 1995. Estimating unknown transition times using a piecewise nonlinear mixed-effects model in men with prostate cancer. J. Am. Stat. Assoc., 90: 45-53.
26. Parsons, J. K., Carter, H. B., Platz, E. A., Wright, E. J., Landis, P. and Metter, E. J. 2005. Serum testosterone and the risk of prostate cancer: Potential implications for testosterone therapy. Cancer Epidemiol. Biomarkers Prev., 14(9): 2257-2260.
27. Pauler, D. K. and Finkelstein, D. M. 2002. Predicting time to prostate cancer recurrence based on joint models for non-linear longitudinal biomarkers and event time outcomes. Stat. Med., 21: 3897-3911.
28. Pauler, D. K. and Laird, N. M. 2002. Non-linear hierarchical models for monitoring compliance. Stat. Med., 21: 219-229.
29. Pearson, J. D., Morrell, C. H., Landis, P. K. and Brant, L. J. 1994. Mixed-effects regression models for studying the natural history of prostate disease. Stat. Med., 13: 587-601.
30. Pisani, P., Parkin, D. M., Bray, F. and Ferlay, J. 1999. Estimates of the worldwide mortality from 25 cancers in 1990. Int. J. Cancer, 83: 18-29.
31. Roy, J. and Lin, X. 2000. Latent variable models for longitudinal data with multiple continuous outcomes. Biometrics, 56: 1047-1054.
32. Roy, J. and Lin, X. 2002. Analysis of multivariate longitudinal outcomes with nonignorable dropouts and missing covariates: Changes in methodone treatment practices. J. Am. Stat. Assoc., 97: 40-52.
33. Schafer, J. L. and Yucel, R. M. 2002. Computational strategies for multivariate linear mixed-effects models with missing values. J. Comput. Graphical Stat., 11: 437-457.
34. Shah, A., Laird, N. and Schoenfeld, D. 1997. A random-effects model for multiple characteristics with possibly missing data. J. Am. Stat. Assoc., 92: 775-779.
35. N.W. Shock, R.C. Greulich, R. Andres, E.G. Lakatta, D. Arenberg, and J.D. Tobin, Normal Human Aging: The Baltimore Longitudinal Study of Aging. NIH Publication No. 84-2450, U.S. Government Printing Office, Washington, DC, 1984.
36. Skates, S. J., Pauler, D. K. and Jacobs, I. J. 2001. Screening based on the risk of cancer calculation from Bayesian hierarchical changepoint and mixture models of longitudinal markers. J. Am. Stat. Assoc., 96: 429-439.
37. Slate, E. H. and Clark, L. C. 1999. "Using PSA to detect prostate cancer onset: An application of Bayesian retrospective and prospective change-point identification". In Case Studies in Bayesian Statistics IV, 511-533. New York: Springer.
38. Slate, E. H. and Cronin, K. A. 1997. "Change-point modeling of longitudinal PSA as a biomarker for prostate cancer". In Case Studies in Bayesian Statistics III, 435-456. New York: Springer.
39. Slate, E. H. and Turnbull, B. W. 2000. Statistical models for longitudinal biomarkers of disease onset. Stat. Med., 19: 617-637.
40. Stattin, P., Lumme, S., Tenkanen, L., Alfthan, H., Jellum, E., Hallmans, G., Thoresen, S., Hakulinen, T., Luostarinen, T., Lehtinen, M., Dillner, J., Stenman, U. H. and Hakama, M. 2004. High levels of circulating testosterone are not associated with increased prostate cancer risk: A pooled prospective study. Int. J. Cancer, 108(3): 418-424.
41. Thum, Y. M. 1997. Hierarchical linear models for multivariate outcomes. J. Educ. Behav. Stat., 22: 77-108.
42. Thum, Y. M. and Bhattacharya, S. K. 2001. Detecting a change in school performance: A Bayesian analysis for a multilevel join point problem. J. Educ. Behav. Stat., 26: 443-468.
43. Verbeke, G. and Lesaffre, E. 1996. A linear mixed-effects model with heterogeneity in the random-effects population. J. Am. Stat. Assoc., 91: 217-221.
44. Whittemore, A. S., Lele, C., Friedman, G. G., Stamey, T., Vogelman, J. H. and Orentreich, N. 1995. Prostate-specific antigen as predictor of prostate cancer in black men and white men. J. Nat Cancer Inst., 87: 354-360.